Drug Type Small molecule drug |
Synonyms Elubrixin, Elubrixin tosylate (USAN), SB-656933-AAF (free base) + [5] |
Target |
Action antagonists |
Mechanism CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H25Cl2FN4O7S2 |
InChIKeyCJAUWWGOABMMJX-UHFFFAOYSA-N |
CAS Registry960495-43-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystic Fibrosis | Phase 2 | United States | 28 Sep 2009 | |
Cystic Fibrosis | Phase 2 | Canada | 28 Sep 2009 | |
Cystic Fibrosis | Phase 2 | France | 28 Sep 2009 | |
Cystic Fibrosis | Phase 2 | Germany | 28 Sep 2009 | |
Cystic Fibrosis | Phase 2 | Israel | 28 Sep 2009 | |
Colitis, Ulcerative | Phase 2 | Netherlands | 22 Jan 2009 | |
Pneumonia | Phase 1 | Germany | 08 Oct 2007 | |
Pulmonary Disease, Chronic Obstructive | Phase 1 | United Kingdom | 04 Jun 2007 |
Phase 2 | 3 | (SB656933 20 mg) | imdttmospu = trgpysfvuw evhxbhilqz (eutpjssulj, xhrwogtudz - zcklczxycb) View more | - | 14 Mar 2018 | ||
(SB656933 100 mg) | ncnulufndi = fbsiqamhqo ljmtzqgmoa (ipuiwzzoni, wufphyhojv - olsccetaio) View more | ||||||
Phase 2 | 146 | Placebo | trwmduksgl = biksvapfqy yvayjrwwtb (nnjiotqmgg, yolpfjhzsx - dmqoawnwbg) View more | - | 17 Nov 2017 |